10 Oct 2017
Typically prescribed for perimenopausal and postmenopausal women to manage vasomotor symptoms, cBHT is not regulated or approved by the FDA and therefore is not a recommended treatment option, experts report in Viewpoint in JAMA Internal Medicine.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024